The long-predicted pharmaceutical innovation crisis has arrived.  New drug approvals for big pharma can no longer replace sales lost to generics; $130 billion of US sales face patent expiration; R&D spending is under the knife; and the patent cliffs ahead could make things worse.  Yet, as the industry faces commoditization, the ingredients of success are at hand:  we have talent, capital, and an accumulating number of cutting-edge discoveries waiting to be translated into useful therapies.How to combine these ingredients into a winning recipe?This session will explore the key questions that define a successful drug R&D organization:  what is the focus? how to manage it? how to fund it? how to mitigate risk effectively?  It will draw upon what research has shown to produce innovation, and will offer actionable ideas to rebut the dire predictions about the industry.

How to beat back the commoditzation of the pharmaceutical industry?

242nd National Meeting (2011)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.